News & Updates

Show Multimedia Only

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025 by

Fremanezumab appears to provide a two-for-one benefit in patients with migraine and comorbid depressive disorder, with data from the UNITE study showing that the drug helped reduce migraine days and lift mood.

Fremanezumab tackles migraine, depression at the same time

16 Jun 2025

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025 by

Treatment with SGLT2 inhibitors can prolong the life of patients with amyloidosis with or without a diagnosis of heart failure (HF), a study has shown.

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

15 Jun 2025 by

Treatment with targeted-release budesonide formulation preserves kidney function and reduces proteinuria in patients with IgA nephropathy (IgAN) independent of baseline eGFR, and this benefit is seen both after 9 months of treatment and throughout the remaining 15-month off-treatment period, according to a subanalysis of the phase III NeflgArd study presented at the ERA annual meeting.

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

15 Jun 2025

Low-dose morphine may do more harm than good for COPD patients with chronic breathlessness

15 Jun 2025

Treatment with steady-state, low-dose morphine does not appear to improve sleep efficiency, sleep-disordered breathing frequency, or next-day alertness but may rather result in hypoventilation during sleep in chronic obstructive pulmonary disease (COPD) patients with chronic breathlessness, according to the results of a randomized, double-anonymized, crossover trial.

Low-dose morphine may do more harm than good for COPD patients with chronic breathlessness

15 Jun 2025

Final VEDOKIDS data: Remission with maintenance vedolizumab durable in UC, less so in CD

14 Jun 2025 by

Maintenance treatment with vedolizumab proved safe and effective in paediatric inflammatory bowel disease (IBD), with long-term remission achieved more frequently in children with ulcerative colitis (UC) than in those with Crohn’s disease (CD), according to the final 3-year data from the VEDOKIDS study.

Final VEDOKIDS data: Remission with maintenance vedolizumab durable in UC, less so in CD

14 Jun 2025

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

14 Jun 2025

Treatment with the combination of zanidatamab plus palbociclib and fulvestrant is safe and demonstrates promising antitumour activity in patients with HR-positive, HER2-positive advanced or metastatic breast cancer, according to a phase IIa study.

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

14 Jun 2025

Functional abdominal pain in kids: Drotaverine, peppermint oil similar in head-to-head trial

13 Jun 2025 by

Both drotaverine and peppermint oil are safe and help alleviate abdominal pain in children whose pain cannot be attributed to a specific medical condition, with neither treatment demonstrating clear superiority over the other, according to the results of a single-blind, randomized controlled trial.

Functional abdominal pain in kids: Drotaverine, peppermint oil similar in head-to-head trial

13 Jun 2025

Phone-based strategy supports BP control after a stroke

13 Jun 2025 by

A nurse-led mobile health (mHealth) intervention that utilizes basic phones improves blood pressure (BP) control among stroke survivors in Ghana, as shown in the phase III PINGS-2 trial.

Phone-based strategy supports BP control after a stroke

13 Jun 2025

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

12 Jun 2025

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), anlotinib plus pepulimab appears to significantly increase progression-free survival (PFS) and overall survival (OS) compared with sorafenib, as shown in the results of the phase III APOLLO study conducted in China.

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

12 Jun 2025

SHR-A1811 shows promise vs HER2-positive breast cancer

12 Jun 2025 by

The third-generation human epidermal growth factor receptor 2 (HER2)-directed antibody‒drug conjugate (ADC) SHR-A1811 has passed its phase II trial, demonstrating safety and efficacy in the neoadjuvant setting for patients with HER2-positive breast cancer.

SHR-A1811 shows promise vs HER2-positive breast cancer

12 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Fremanezumab tackles migraine, depression at the same time

Fremanezumab tackles migraine, depression at the same time

SGLT2i extends survival in amyloidosis patients with or without HF

SGLT2i extends survival in amyloidosis patients with or without HF

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

Targeted-release budesonide formulation makes good in IgAN regardless of baseline eGFR

Low-dose morphine may do more harm than good for COPD patients with chronic breathlessness

Low-dose morphine may do more harm than good for COPD patients with chronic breathlessness

Final VEDOKIDS data: Remission with maintenance vedolizumab durable in UC, less so in CD

Final VEDOKIDS data: Remission with maintenance vedolizumab durable in UC, less so in CD

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

Functional abdominal pain in kids: Drotaverine, peppermint oil similar in head-to-head trial

Functional abdominal pain in kids: Drotaverine, peppermint oil similar in head-to-head trial

Phone-based strategy supports BP control after a stroke

Phone-based strategy supports BP control after a stroke

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

SHR-A1811 shows promise vs HER2-positive breast cancer

SHR-A1811 shows promise vs HER2-positive breast cancer